Charles Schwab’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-612,126
| Closed | -$29.1M | – | 3457 |
|
|
2025
Q3 | $29.1M | Sell |
612,126
-2,140
| -0.3% | -$104K | ﹤0.01% | 1488 |
|
|
2025
Q2 | $32.8M | Buy |
614,266
+32,012
| +5% | +$1.45M | 0.01% | 1370 |
|
|
2025
Q1 | $23.6M | Buy |
582,254
+41,562
| +8% | +$1.76M | ﹤0.01% | 1549 |
|
|
2024
Q4 | $15M | Buy |
540,692
+8,096
| +2% | +$245K | ﹤0.01% | 1837 |
|
|
2024
Q3 | $15.3M | Sell |
532,596
-22,269
| -4% | -$581K | ﹤0.01% | 1837 |
|
|
2024
Q2 | $13M | Buy |
554,865
+36,579
| +7% | +$782K | ﹤0.01% | 1907 |
|
|
2024
Q1 | $13.1M | Buy |
518,286
+92,741
| +22% | +$2.23M | ﹤0.01% | 1844 |
|
|
2023
Q4 | $9.94M | Buy |
425,545
+6,115
| +1% | +$121K | ﹤0.01% | 1991 |
|
|
2023
Q3 | $21.2M | Buy |
419,430
+124,768
| +42% | +$5.81M | 0.01% | 1475 |
|
|
2023
Q2 | $13.8M | Buy |
294,662
+56,315
| +24% | +$2.58M | ﹤0.01% | 1741 |
|
|
2023
Q1 | $9.12M | Buy |
238,347
+1,750
| +0.7% | +$78K | ﹤0.01% | 1918 |
|
|
2022
Q4 | $13M | Buy |
236,597
+23,578
| +11% | +$1.01M | ﹤0.01% | 1705 |
|
|
2022
Q3 | $7.25M | Buy |
213,019
+48,196
| +29% | +$737K | ﹤0.01% | 2019 |
|
|
2022
Q2 | $1.56M | Sell |
164,823
-8,723
| -5% | -$90.9K | ﹤0.01% | 2640 |
|
|
2022
Q1 | $2.46M | Sell |
173,546
-706
| -0.4% | -$12.4K | ﹤0.01% | 2571 |
|
|
2021
Q4 | $3.69M | Buy |
174,252
+8,899
| +5% | +$197K | ﹤0.01% | 2503 |
|
|
2021
Q3 | $3.7M | Buy |
165,353
+26,360
| +19% | +$597K | ﹤0.01% | 2513 |
|
|
2021
Q2 | $3.45M | Buy |
138,993
+27,882
| +25% | +$783K | ﹤0.01% | 2530 |
|
|
2021
Q1 | $3.22M | Buy |
111,111
+3,179
| +3% | +$96.2K | ﹤0.01% | 2505 |
|
|
2020
Q4 | $2.79M | Buy |
107,932
+119
| +0.1% | +$3.31K | ﹤0.01% | 2492 |
|
|
2020
Q3 | $3.32M | Buy |
107,813
+56,868
| +112% | +$1.99M | ﹤0.01% | 2281 |
|
|
2020
Q2 | $1.27M | Buy |
50,945
+6,619
| +15% | +$151K | ﹤0.01% | 2559 |
|
|
2020
Q1 | $940K | Buy |
44,326
+8,102
| +22% | +$174K | ﹤0.01% | 2506 |
|
|
2019
Q4 | $804K | Buy |
36,224
+3,935
| +12% | +$81.4K | ﹤0.01% | 2671 |
|
|
2019
Q3 | $735K | Buy |
+32,289
| New | +$751K | ﹤0.01% | 2659 |
|
Other funds holding AKRO
Charles Schwab's AKRO Position: Q4 2025 in Review
Charles Schwab sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 612,126 shares — an estimated $29.1M sold.
Charles Schwab first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $32.8M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Charles Schwab reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Charles Schwab sold 612,126 Akero Therapeutics shares in Q4 2025, an estimated $29.1M.
- Charles Schwab first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
- Charles Schwab's Akero Therapeutics position peaked at $32.8M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Charles Schwab's 13F filing for Q4 2025, filed 13 Feb 2026.